Global Fluorescent In Situ Hybridization Probe Market 2026 – 2035

The market size of global fluorescent in situ hybridization probe is estimated to reach USD 1.14 billion in 2025 and to grow between USD 1.23 billion in 2026 and an estimated USD 2.27 billion by 2035 with a CAGR of 7.9% in 2026 through 2035. The market is growing due to the increasing number of cancer and genetic diseases, the growing use of personalized medicine and companion diagnostics, the development of new technology in multiplex FISH and automated imaging, and the growing body of research in the areas of genomics and molecular biology.

Market Highlight

• In North America the market share in North America reached 47% of the fluorescent in situ hybridization probe in 2025.

• Asia Pacific will grow at the sweeter rate of 8.6% over the period, 2026-2035.

• Instrument and systems segment had almost 42% point of the market share in 2025 by product type.

• By probe type, the DNA probes segment is enjoying a dominant position of 45% in 2025, with RNA probes segment with the highest CAGR of 8.8% between 2026 and 2035.

• Applied, cancer diagnostics segment recorded the largest market share of 44% in 2025, and genetic disorder diagnosis segment had a CAGR of 9.2% in the period projected between 2026 and 2035.

• By end-user, the segment of hospitals and diagnostic laboratories took 48% of the market share in 2025.

Significant Growth Factors

The Fluorescent In Situ Hybridization Probe Market Trends present significant growth opportunities due to several factors:

• Rising Prevalence of Cancer and Genetic Disorders Requiring Molecular Diagnostics: The main force of the FISH probe market is the growing number of cancer and hereditary genetic diseases worldwide, and the changes in the number of chromosomes and the occurrence of gene mutations become the main force of diagnosing diseases, prognosis, and the choice of treatment. The American Cancer Society 2025 data has revealed that the US alone would experience more than 2 million new cancer cases, which do not include non melanoma skin cancers, and this indicates the vast and increasing oncology patient population that is in need of accurate genetic testing. FISH testing is especially important in the diagnostic of breast cancer because it involves probes that identify additional copies of the HER2 genes that determine the response of the patient to specific treatments such as trastuzumab. FISH is used to detect translocations between chromosomes, including Philadelphia chromosome in chronic myeloid leukemia and BCR-ABL fusion in acute lymphoblastic leukemia, and has a direct effect on treatment choices in hematologic malignancies. Clinical studies have found that FISH is more statistically accurate and discriminatory than the traditional karyotyping techniques in the detection and diagnostics of cancer, and has the capability to identify abnormalities too small to be detected by other cytogenetic methods. FISH has been extensively used in the diagnosis of genetic syndromes such as Down syndrome and DiGeorge syndrome, and the results of the technique are fast, making it especially useful in prenatal diagnosis and neonatal screening where quick diagnosis and subsequent intervention can be life-saving. Genetic disorders burden the world community with millions of affected individuals with about 6% of all babies born globally having congenital abnormality or genetic disease necessitating special diagnostic assessment. The growing number of patients in need of chromosomal and genetic analysis establishes long-term demand of the FISH probes in the field of oncology, prenatal testing, postnatal diagnosis, and research. Recent technologies of FISH probes have also added additional features such as multiplexing that can detect multiple genetic targets at once, better signal amplification to increase sensitivity, and forms compatible with automation in high throughput laboratories and deep learning integration with digital pathology to allow AI-assisted analysis and interpretation of images.

• Technological Advancements and Integration with Precision Medicine Initiatives: The evolution of technology and the incorporation of FISH probes into precision medicine and companion diagnostic models promoted the fast development of the market significantly. Some novel innovations are multiplex FISH technologies that allow visualizing multiple chromosomal areas at once with various different fluorescent labels, FLOW-FISH that integrates flow cytometry with in situ hybridization to analyze gene expression patterns on a high-throughput scale, quantitative FISH that allows making an accurate count of copies of a particular gene to be detected, and RNA-FISH that can detect specific mRNA sequences. In 2025, more than 54% of research centres will switch to multiplex FISH probe technology and 52% of oncology labs will use FISH probes to detect chromosomal translocation in 2024. Recent application the modern FISH systems have automated imaging platforms with AI-driven interpretation that can be found to enhance detection efficiency by 29%, the ability to have digital pathology integration that allows remote consultation and quality control, and cloud-based data management that can support multi-site research collaborations. An example is that in January 2025, Molecular Instruments introduced the HCR Gold and HCR Pro product lines with the underlying HCR imaging platform redefining the multiplexed, quantitative, and high-resolution RNA-FISH in thick, autofluorescent samples. In January 2025, Roche was approved by the US FDA with its PATHWAY HER2 test being the first HER2-ultralow companion diagnostic of metastatic breast cancer with high concordance with HER2 FISH probes, and greater eligibility to targeted therapy. F. Hoffmann-La Roche was granted FDA 510(k) clearance of the VENTANA Kappa and Lambda Dual ISH seeing the first clinically approved ISH assay with sensitivity to determine the entire range of B-cell lymphoma subtypes in January 2025. Moreover, new methods in medicine, such as locked nucleic acid or modified peptide nucleic acid probes with stronger binding affinity, quantum dot labeled probes with better photostability and brighter signals, and new methods of genetic analysis have been made possible through medical innovation in probe design. The ongoing product development by major manufacturers such as Thermo Fisher Scientific, Agilent Technologies, Abbott Laboratories, and F. Hoffmann-La Roche has continued to grow product offerings with their increased product development projects since 2023 to 2025 and the adoption of these new probe technologies has been encouraged in the clinical diagnostics, pharmaceutical development, and academic research environments.

What are the Major Advances Changing the Fluorescent In Situ Hybridization Probe Market Today?

• Multiplex FISH and Multi-Color Imaging Technologies : The possibility to multiplex FISH is one of the most important technical innovations as it allows identifying a number of genetic targets in one assay using various fluorescent labels. Multiplex FISH is much more efficient in the laboratory, so it uses fewer individual assays, conserves valuable clinical samples, and offers extensive genetic profiling that would otherwise be obscured under single-target assays to indicate complex chromosomal rearrangements. Developed multiplex systems are capable of visualizing 5 or more aspects of chromosomal region at a time spectral imaging and multispectral analysis software deconvolutes overlapping fluorescent images to give precise genetic information. Almost half of the research facilities are moving to multiplex FISH probe technology as the most important technique to obtain advanced diagnostics as the new technology has proven to be more informative and cost-efficient with multi-target analysis. Multiplex methods are especially useful in cancer cytogenetics where multifaceted karyotypes defined by multiple chromosomal abnormalities are common of most cancers and in prenatal screening where global measurement of aneuploidy across multiple chromosomes helps improve the accuracy of diagnosis.

• FLOW-FISH Technology for High-Throughput Analysis : This is the combination of flow cytometry with fluorescence in situ hybridization that has made a breakthrough in genetic analysis and allowed a rapid and quantitative examination of thousands of individual cells. FLOW-FISH is the shareholder with the highest technology with a 35.8% share in 2024 and the fastest-growing segment with its unique combination that provides high-throughput and quantitative analysis of nucleic acids down to the single-cell level. This approach is also applied in telomere length studies where it offers highly accurate quantitation that is important in aging studies and cancer biology, diagnosis of hematologic malignancies that can be rapidly screened using the method, and stem cell research to define cellular heterogeneity in a population. FLOW-FISH is able to process more than 10,000 cells in 10 minutes, which is 20 to 100 times higher than manual FISH testing and offers much higher levels of repeatability and standardization. Automation and objectivity of FLOW-FISH is a solution to long-term drawbacks of manual FLOW-FISH analysis such as inter-observer variance, microscopic examination, which requires labor and sampling of cell population.

• AI-Powered Automated Image Analysis and Digital Pathology : The introduction of artificial intelligence and machine learning algorithms to analyze FISH signals automatically solves key bottlenecks of FISH analytics in the test workflow. In 2023, AI-enhanced FISH probe imaging systems doubled the detection rate of artificial intelligence-enhanced systems and automated systems cut the analysis time by half and showed greater consistency and accuracy than human microscopic analysis. Detection schemes are computer-aided schemes that automatically locate cell nuclei, find and count locations of fluorescent signal spots, categorize pattern of signal as normal or abnormal, and produce quantitative reports without subjectivity variability. The reliability of automated analysis is proven by studies that have shown that Kappa coefficients of agreement between CAD and human observers detecting FISH signals are between 0.69 and 1.0. Online pathology systems provide the capabilities to capture the entire slide on FISH, remote consultations allowing specialists to review complicated cases irrespective of their geographic position, provide quality checks by means of central review of the distributed test location, and allow the full archival of images that could be used in longitudinal patient follow-up and research. Combination of AI with digital FISH can be used to aid new uses such as spatial transcriptomics where RNA-FISH analysis can be coupled with tissue morphology to deliver new insights into the patterns of gene expression within tissue architecture.

• Companion Diagnostics and Therapy-Linked Precision Testing : The timing of the transition of the FISH probe usage to that of general cancer diagnosis to the usage of this technology as companion diagnostics directly associated with a particular therapy is a significant trend in the market. When FDA accepts FISH companion diagnostics, FISH testing is compulsory in the selection of targeted therapy, which directly stimulates the adoption and the market base is broadened. To illustrate, the FDA granted a PMA supplement to the Vysis ALK Break Apart FISH Probe Kit to incorporate an indication of ENSACOVE in non-small cell lung cancer to associate the Fisher FISH testing with treatment decisions. This trend signifies the shift in the general usage of diagnostics to precision testing associated with therapy, which does not only enhance the use of FISH probes in a clinical setting but also adds to their role in directing targeted cancer therapy. The use of HER2 FISH tests in breast cancer defines the suitability of HER2-targeted therapies, with the most recent approvals of FDA expanding the test to include HER2-ultralow-patients, widening potentially eligible population group of patients. Such regulatory support guarantees long-term demand, driving a steady growth in the market as drug-makers come up with focussed therapy that necessitates companion diagnostics.

Category Wise Insights

By Product Type

Why Instruments and Systems Lead the Market?

The largest segment is the 2025 instruments and systems which will occupy about 42% of the market share. Such superiority is indicative of the complex instrumentation needed to conduct FISH procedures properly, and the successful implementation of FISH technique relies on the quality of fluorescence microscopes, automated imaging and hybridization platforms, which directly influence the accuracy of the diagnoses and the quality of research. State-of-the-art FISH microscopy systems have multiple excitation/ emission filters, multiplex analysis, high sensitivity cameras with the capability of detecting weak fluorescent signals, motorized stages to allow scan of full specimen, and built-in software to capture and analyze the image. Automated imaging systems help deal with workflow bottlenecks by automating slide scanning, providing consistent focus and exposure on entire specimens and allowing a high throughput scale of processing required in clinical laboratories with large volumes of tests.

The probes and kits segment is a significant market share with locus-specific probes dominating the FISH probe market projected to 32.5% in 2025. Locus specific probes are based on specific defined regions of chromosomes in order to identify amplifications of genes, deletions or translocations of gene sequences of vital importance in cancer diagnosis and identification of genetic disorders. Application Centromeric probes allow chromosome enumeration of aneuploidy in prenatal screening and cancer cytogenetics, whereas whole chromosome painting probes can be used to visualize entire chromosomes that can be used to identify complex translocations and define karyotype abnormalities. Designing of tailor-made FISH probes to uncommon genetic disorders and to novel research uses is also a market that is expanding, and probe design services are provided by manufacturers to allow the researcher to design probes to specific regions of interest in the genome.

By Probe Type

Why DNA Probes Dominate the FISH Market?

DNA probes are the biggest, which will have around 45% of the market share in 2025. The current application in cytogenetics of DNA-FISH in the detection of chromosomal abnormalities that are essential in the diagnosis of genetic diseases and cancer deserves this leadership role. Numerical abnormalities of the chromosomes, such as trisomies and monosomies, structural rearrangements, such as translocations and inversion, Gene amplification with its subsequent increase, and micro deletions too small to be detected by standard karyotyping methods are all detected by use of DNA FISH probes. DNA FISH informs treatment choices in oncology by revealing predictive changes in genes of response to therapy, and HER2 amplification testing of breast cancer is among the most intensive uses of FISH in the world. Prenatal diagnostics DNA probes are critical in screening aneuploidy of chromosomes, 13, 18, 21, X, and Y within 24-48 hours as opposed to weeks in case of traditional karyotyping.

The fastest growth rate of 8.8% between 2026 and 2035 is predicted in RNA probes, which has a growing number of applications in the field of gene expression analysis, infectious disease detection, and studies in the area of spatial transcriptomics. RNA-FISH allows one to visualize individual mRNA molecules in intact cells and tissues, which gives spatial information of gene expression patterns that bulk RNA sequencing methods do not have. Recent technological developments such as hybridization chain reaction (HCR) amplification have revolutionized RNA-FISH sensitivity allowing individual molecules of the macroprokaryote to be detected in difficult specimens. The introduction of such products as the Molecular Instruments HCR Gold and HCR Pro product lines has become the advanced technology in RNA-FISH, which provides multiplexed, quantitative, high-resolution imaging of thick, autofluorescent samples. RNA probes are finding applications in the infectious disease diagnostics of identifying viral and bacterial nucleic acids, in neuroscience research of mapping gene expression in brain tissues and in cancer biology to study tumor heterogeneity on a transcriptional scale.

By Application

Why Cancer Diagnostics Dominates FISH Applications?

The highest application segment is cancer diagnostics at an estimated of 44% of the total market share in 2025. The critical role of FISH in identifying the genetic abnormalities that characterize cancer subtypes, predict the prognosis, and inform the choice of targeted therapy relates to this leadership position. FISH testing of breast cancer is frequently done to examine the amplification of the HER2 gene to determine eligibility to HER2-targeted therapy that has revolutionized the treatment of HER2-positive patients. In hematologic malignancies, FISH is used to identify typical translocations of chromosomes, such as the Philadelphia chromosome (BCR-ABL fusion) in chronic myeloid leukemia and acute lymphoblastic leukemia, translocation characteristic of acute promyelocytic leukemia and translocations in the classification and prognosis of lymphomas. By 2024, about 52% of oncology laboratories had increased the FISH probe application in the detection of translocation of chromosomes as an indication of the increasing awareness of the role of molecular genetics in cancer management.

The trend towards companion diagnostics has increased the use of cancer FISH, FDA approvals require particular FISH tests to be used in the selection of therapies. As an example, non-small cell lung cancer prescribed with ALK inhibitors needs to undergo ALK rearrangement testing by FISH, whereas ROS1 rearrangement testing involves determining patients who are allowed to have crizotinib therapy. Such regulatory demands generate long-lasting demand of certain FISH probes that are associated with approved targeted therapeutic compounds. FISH additionally offers prognostic data regardless of the choice of therapy, and some chromosome abnormalities in chronic lymphocytic leukemia correlate with severe disease progression and relapse to therapy.

The rapidest expansion is in genetic disorder diagnosis at a projected CAGR of 9.2% between 2026 and 2035 as a result of the growing newborn screening systems, better understanding of genetic disorders and the availability of genetic testing systems to a larger population. FISH can be used to diagnose common aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13) within a short period of time in either the prenatal or postnatal environment. Specific FISH probes of these areas are used to diagnose microdeletion syndromes (DiGeorge syndrome (22q11.2 deletion), Williams syndrome (7q11.23 deletion), and Prader-Willi/Angelman syndromes (15q11-q13 deletions) which are definitively diagnosed on clinical suspicion.

By End-User

Why Hospitals and Diagnostic Laboratories Lead Adoption?

The largest end-user segment would be hospitals and diagnostic laboratories and the market share of them will be about 48% in 2025. This is the dominance of FISH testing in clinical practice where the outcomes directly influence the diagnosis and treatment decisions of patients. Clinical laboratories that conduct FISH have large stocks of specimens, have staff of highly trained specialized cytogenetic technologists trained in FISH procedures, quality control measures that assure accuracy of results and proficiency testing programs that ensure regulatory compliance. Hospital-based FISH services are complementary to various clinical specialties such as oncology that needs cancer diagnosis and monitoring, obstetrics that needs prenatal testing, pediatrics that requires the diagnosis of congenital anomalies, and hematology that needs the diagnosis of blood disorders. FISH probes are highly sensitive and specific, and are regularly applied in the diagnosis of genetic diseases, cancers and infectious diseases, so that in clinical applications they have equal shares (48%) of the market share of usage according to market data.

Research and academic institutes are another significant and increasing end-user segment, which is expected to increase at the highest CAGR within the forecast period. The FISH probes are also done through academic researchers in the study of the disease mechanisms as well as the validation of the genomic discoveries as well as gene expression patterns as well as in the study of the evolutionary genomics in an inter-species study. Increasing spatial transcriptomics and single-cell analysis technologies means that academic institutions are actively seeking new technologies in FISH, and 47% of genetic research institutions center their studies on mRNA probe-based research in 2024. Custom probe development services are useful to universities and research centers to investigate new genetic targets that are not represented by commercial probe collections. In February 2025, Bio-Techne increased its RNAscope ISH probes menu to obtain a total of 70,000 one-of-a-kind probes across over 450 species to address the various needs of professionals researching in different areas of the world.

Report Scope

Regional Analysis

How Big is the North America Market Size?

The North America fluorescent in situ hybridization probe market size is estimated at USD 536 million in 2025 and is projected to reach approximately USD 1,078 million by 2035, with an 8.0% CAGR from 2026 to 2035.

Why did North America Dominate the Market in 2025?

North America is the most influential force in the world, with its market share of around 47% in 2025 due to the high focus on biomedical research and well-developed healthcare infrastructure, including well-developed hospitals and clinical labs, rising cases of genetic illnesses and cancer, well-developed regulation framework to support companion diagnostics, and the presence of major manufacturers and innovative biotechnology companies. The US takes the lead in the market due to increasing incidences of cancer that have more than 2 million new cases per year and targeted support in research and development through academic institutions and pharmaceutical firms.

What is the Size of the U.S. Market?

The market size of the U.S. fluorescent in situ hybridization probe is estimated at USD 428 million in 2025 and the size is projected to hit almost USD 858 million in 2035 with a high CAGR of 8.1% between 2026 and 2035.

U.S. Market Trends

The US market is the largest market globally that is propelled by FDA approvals of FISH companion diagnostics that compel testing as a requisite in the selection of targeted therapy, multiple grants awarded by the National Institutes of Health on genetic and oncology research, initial regulatory approvals of advanced FISH-based diagnostic tests, and extensive reimbursement by Medicare as well as commercial insurance. In 2023, the Northeast region became dominant in the U.S. market, which was advantaged with the concentration of academic medical centers, biotechnology companies and pharmaceutical research facilities in this region.

Why is Asia Pacific Experiencing the Fastest Growth?

It is expected that the Asia-Pacific region will represent the highest growth with a CAGR of 8.6% between 2026 and 2035. The fast growth is a signal of the investments in healthcare infrastructure development with the increasing number of diagnostic laboratories, governmental support of biotechnology development, increasing use of precision medicine and personalized diagnostics, technology transfer and collaboration with the Western community, and large population groups that generate a large patient base. In 2024, capital flow toward diagnostic innovation in China increased by 29%, and nations throughout the region are rapidly switching to precision medicine boosting FISH probe demand.

China Market Trends

The Chinese market is growing fast due to the government investment in biotechnology development, the development of domestic pharmaceutical and biotechnology firms such as local manufacturers such as Bioneer Corporation and Myleus Biotechnology, the growth of clinical diagnostic infrastructure, and the growing numbers of international diagnostic standards being adopted. The Chinese policy of medical equipment upgrading of July 2024 speeds up the purchase of high-level molecular diagnostic equipment such as FISH in county hospitals.

Why is Europe Entering a New Era?

The European market is big and mature with a high level of healthcare systems, full-fledged molecular diagnosis facilities, a heavy stress on quality diagnostics, and well-developed research facilities. Europe controlled a share of around 25% of the market share at the global market, with Germany controlling 26.3% of the European market share in 2025 on the basis of the presence of the pharmaceutical and biotech industry and strict healthcare regulations enforcing correct diagnostics in the country. Research networks and harmonization of regulations of the region contribute to the support of diagnostic innovation.

Germany Market Trends

Germany is considered to possess one of the largest markets in Europe, which is due to the developed pharmaceutical sector, large number of biotechnology firms, well-developed clinical diagnostics network, and well-hosted academic research. German plants have early use of new technologies such as multiplex FISH and automated imaging technologies.

Why is the Middle East & Africa Region Accelerating Adoption?

There is diverse market growth in the LAMEA region with the growing adoption due to the rising cancer incidence, the rising awareness of genetic disorders, and better health infrastructure. The Middle East, specifically the UAE and South Africa, illustrates the scope of investment in the development of advanced diagnostics with the help of the partnerships with the state and the growing facilities of molecular tests. The governmental aid in sophisticated diagnostic instruments and the development of networks of laboratories contribute to the increase of the market.

Brazil Market Trends

The market development in Brazil is due to the expansion of the private healthcare sector, the rise in pharmaceutical research and development and the increased demand for molecular diagnostic services. In September 2024, Hospitex and BIO BRASIL BIOTECNOLOGIA have announced that they intend to enhance their relationship that will expand cytology services throughout Brazil, and this will improve diagnostic possibilities and early detection of diseases.

Top Players in the Market and Their Offerings

• Thermo Fisher Scientific Inc.

• Abbott Laboratories

• Agilent Technologies Inc.

• F. Hoffmann-La Roche Ltd.

• PerkinElmer Inc.

• Bio-Rad Laboratories Inc.

• Oxford Gene Technology (Sysmex)

• Abnova Corporation

• Empire Genomics LLC

• MetaSystems Group

• Others

Key Developments

The market has experienced a lot of developments with the players in the industry trying to increase their capabilities and increase their product lines.

• In March 2025: Vitro Master Diagnóstica announced the appointment of Biocare Medical as the exclusive distributor for its new NeoPATH Pro instrument in the United States. The NeoPATH Pro is a high-throughput platform with 42-slide capacity, supporting advanced immunohistochemistry, in situ hybridization, and fluorescence in situ hybridization applications. (Source: Vitro Master Diagnostics)

• In February 2025: Bio-Techne expanded its RNAscope in situ hybridization probes menu to over 70,000 unique probes across more than 450 species for human and mouse transcriptomes to support spatial biology research applications. (Source: Bio-Techne Corporation)

These strategic moves have seen companies gaining market strength, increasing product offerings, and, by the growing market, companies have taken advantage of growth prospects in the market.

The Fluorescent In Situ Hybridization Probe Market is segmented as follows:

By Product Type

• Instruments and Systems

  • Fluorescence Microscopes

  • Automated Imaging Systems

  • Flow Cytometry Systems

• Probes and Kits

  • Locus-Specific Probes

  • Centromeric Probes

  • Whole Chromosome Probes

  • Custom Probes

• Consumables

  • Reagents and Buffers

  • Slides and Coverslips

• Software and Services

By Probe Type

• DNA Probes

• RNA Probes

• PNA Probes (Peptide Nucleic Acid)

By Application

• Cancer Diagnostics

  • Breast Cancer

  • Hematologic Malignancies

  • Solid Tumors

• Genetic Disorder Diagnosis

• Prenatal Testing

• Research Applications

• Other Applications

By End-User

• Hospitals and Diagnostic Laboratories

• Research and Academic Institutes

• Pharmaceutical and Biotechnology Companies

• Contract Research Organizations

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America